Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients

Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by a...

Full description

Bibliographic Details
Main Authors: Kosuke Kaji, Soichiro Saikawa, Hiroaki Takaya, Yukihisa Fujinaga, Masanori Furukawa, Koh Kitagawa, Takahiro Ozutsumi, Daisuke Kaya, Yuki Tsuji, Yasuhiko Sawada, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/9/4/145
id doaj-8798b1fe9cdc4fa18411d8387cb72231
record_format Article
spelling doaj-8798b1fe9cdc4fa18411d8387cb722312020-11-25T02:23:05ZengMDPI AGAntibiotics2079-63822020-03-01914514510.3390/antibiotics9040145Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic PatientsKosuke Kaji0Soichiro Saikawa1Hiroaki Takaya2Yukihisa Fujinaga3Masanori Furukawa4Koh Kitagawa5Takahiro Ozutsumi6Daisuke Kaya7Yuki Tsuji8Yasuhiko Sawada9Hideto Kawaratani10Kei Moriya11Tadashi Namisaki12Takemi Akahane13Akira Mitoro14Hitoshi Yoshiji15Department of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanDepartment of gastroenterology, Nara Medical University, Kashihara 634-8522, JapanRifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by ammonia level, neuropsychological testing, endotoxin activity (EA), and serum proinflammatory cytokines at baseline and after four weeks of rifaximin treatment (1200 mg/day). Intestinal permeability was indicated by serum soluble CD163 (sCD163), mannose receptor (sMR), and zonulin levels. To evaluate the gut microbiome, 16S ribosomal RNA gene sequencing was applied. Rifaximin ameliorated hyperammonemia and cognitive dysfunction, although it did not change the serum proinflammatory cytokine levels. It decreased EA levels as well as serum levels of sCD163 and sMR, but not zonulin, and both decreases in sCD163 and sMR showed positive correlations with EA decrease (ΔsCD163: Correlation coefficient (R) = 0.680, <i>p</i> = 0.023; ΔsMR: R = 0.613, <i>p</i> = 0.014, vs. ΔEA). Gut microbial analysis revealed that the richness and complexity of species were unchanged while the abundance of the <i>Streptococcus</i> genus was reduced after treatment with rifaximin. Collectively, rifaximin alleviated HE and endotoxemia with improved intestinal hyperpermeability in patients with decompensated cirrhosis, and this effect is partially involved in a gut microbial change.https://www.mdpi.com/2079-6382/9/4/145cirrhosisendotoxinmicrobiomerifaximin
collection DOAJ
language English
format Article
sources DOAJ
author Kosuke Kaji
Soichiro Saikawa
Hiroaki Takaya
Yukihisa Fujinaga
Masanori Furukawa
Koh Kitagawa
Takahiro Ozutsumi
Daisuke Kaya
Yuki Tsuji
Yasuhiko Sawada
Hideto Kawaratani
Kei Moriya
Tadashi Namisaki
Takemi Akahane
Akira Mitoro
Hitoshi Yoshiji
spellingShingle Kosuke Kaji
Soichiro Saikawa
Hiroaki Takaya
Yukihisa Fujinaga
Masanori Furukawa
Koh Kitagawa
Takahiro Ozutsumi
Daisuke Kaya
Yuki Tsuji
Yasuhiko Sawada
Hideto Kawaratani
Kei Moriya
Tadashi Namisaki
Takemi Akahane
Akira Mitoro
Hitoshi Yoshiji
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
Antibiotics
cirrhosis
endotoxin
microbiome
rifaximin
author_facet Kosuke Kaji
Soichiro Saikawa
Hiroaki Takaya
Yukihisa Fujinaga
Masanori Furukawa
Koh Kitagawa
Takahiro Ozutsumi
Daisuke Kaya
Yuki Tsuji
Yasuhiko Sawada
Hideto Kawaratani
Kei Moriya
Tadashi Namisaki
Takemi Akahane
Akira Mitoro
Hitoshi Yoshiji
author_sort Kosuke Kaji
title Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
title_short Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
title_full Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
title_fullStr Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
title_full_unstemmed Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
title_sort rifaximin alleviates endotoxemia with decreased serum levels of soluble cd163 and mannose receptor and partial modification of gut microbiota in cirrhotic patients
publisher MDPI AG
series Antibiotics
issn 2079-6382
publishDate 2020-03-01
description Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis. Thirty patients with decompensated cirrhosis were assessed by ammonia level, neuropsychological testing, endotoxin activity (EA), and serum proinflammatory cytokines at baseline and after four weeks of rifaximin treatment (1200 mg/day). Intestinal permeability was indicated by serum soluble CD163 (sCD163), mannose receptor (sMR), and zonulin levels. To evaluate the gut microbiome, 16S ribosomal RNA gene sequencing was applied. Rifaximin ameliorated hyperammonemia and cognitive dysfunction, although it did not change the serum proinflammatory cytokine levels. It decreased EA levels as well as serum levels of sCD163 and sMR, but not zonulin, and both decreases in sCD163 and sMR showed positive correlations with EA decrease (ΔsCD163: Correlation coefficient (R) = 0.680, <i>p</i> = 0.023; ΔsMR: R = 0.613, <i>p</i> = 0.014, vs. ΔEA). Gut microbial analysis revealed that the richness and complexity of species were unchanged while the abundance of the <i>Streptococcus</i> genus was reduced after treatment with rifaximin. Collectively, rifaximin alleviated HE and endotoxemia with improved intestinal hyperpermeability in patients with decompensated cirrhosis, and this effect is partially involved in a gut microbial change.
topic cirrhosis
endotoxin
microbiome
rifaximin
url https://www.mdpi.com/2079-6382/9/4/145
work_keys_str_mv AT kosukekaji rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT soichirosaikawa rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT hiroakitakaya rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT yukihisafujinaga rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT masanorifurukawa rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT kohkitagawa rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT takahiroozutsumi rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT daisukekaya rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT yukitsuji rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT yasuhikosawada rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT hidetokawaratani rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT keimoriya rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT tadashinamisaki rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT takemiakahane rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT akiramitoro rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
AT hitoshiyoshiji rifaximinalleviatesendotoxemiawithdecreasedserumlevelsofsolublecd163andmannosereceptorandpartialmodificationofgutmicrobiotaincirrhoticpatients
_version_ 1724860004641538048